Screener
CorMedix CRMD EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by CorMedix in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: CorMedix’s 10-Q, filed August 13, 2026.
- Filed
- Aug 13, 2026, 8:07 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001410098-26-000056
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Unrealized loss from investments | - | (2) | (1) | (6) |
| Foreign currency translation loss | - | (3) | - | (5) |
| Total Other Comprehensive Loss | - | (5) | (1) | (11) |
| Comprehensive Income | $25,988 | $19,823 | $64,588 | $40,461 |
| Net Income Per Common Share – Basic | $0.33 | $0.29 | $0.81 | $0.60 |
| Net Income Per Common Share - Diluted | $0.29 | $0.28 | $0.72 | $0.58 |
| Weighted Average Common Shares Outstanding – Basic | 78,444 | 67,928 | 78,949 | 66,593 |
| Weighted Average Common Shares Outstanding – Diluted | 92,479 | 71,919 | 92,543 | 70,354 |
Item 1. Unaudited Condensed Consolidated Financial Statements.
FAQ
- What is CorMedix's EPS (diluted)?
- CorMedix (CRMD) reported EPS (diluted) of $0.29 in Q2 2026.
- How has CorMedix's EPS (diluted) changed year-over-year?
- CorMedix's EPS (diluted) increased by 3.6% year-over-year, from $0.28 to $0.29.
- What is the long-term trend for CorMedix's EPS (diluted)?
- Over 3 years (2021 to 2025), CorMedix's EPS (diluted) has grown at a 36.6% compound annual growth rate (CAGR), from -$0.75 to $1.91.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about CorMedix's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude